Indian pharmaceutical tycoon Yusuf Hamied revolutionized AIDS treatment more than a decade ago by supplying cut-price drugs to the world’s poor — and now he wants to do the same for cancer.
Hamied, chairman of generic drugs giant Cipla, last month slashed the cost of three medicines to fight brain, kidney and lung cancer in India, making the drugs up to more than four times cheaper.
“I hope we’ll cut prices of many more cancer drugs,” he said, adding that he wants to supply the cheaper drugs to Africa and elsewhere. “Reducing the price of cancer drugs is a humanitarian move.”
Hamied, 76, was pilloried by Western drug giants 11 years ago when he broke their monopoly by offering to supply life-saving triple therapy AIDS drug cocktails for under US$1 a day — one-thirtieth the price set by the multinationals.
The firms branded him an intellectual property thief while he accused them of being “global serial killers” whose high prices were costing the lives of AIDS patients.
“What he did was path-breaking. It has been very important in saving lives, and what he is doing with cancer drugs is the same,” said Leena Menghaney, a lawyer with humanitarian group Medecins sans Frontieres (Doctors Without Borders).
In 1972, India made only the process for making drugs patentable, not the drugs themselves.
This meant firms could “reverse-engineer” or change methods used to make medicines and sell them at up to one-fiftieth of US prices.
The legislation gave a huge leg-up to India’s generics industry and gave the nation the nickname “the pharmacy to the Third World.”
However, in 2005, India brought its law in line with WTO rules recognizing 20-year patents, pushing up the prices of newly launched drugs.
Cipla, India’s fourth-largest pharmaceutical company by sales, has been pressing the government to allow widespread use of “compulsory licenses,” which are permitted under WTO rules.
The licenses allow companies to make existing life-saving drugs to sell in countries where they are otherwise priced out of reach.
India’s first such license was granted in March to Natco Pharma to produce a generic version of Bayer’s blockbuster kidney cancer drug Nexavar, cutting the price from 28,000 rupees (US$500) for a monthly dose to 6,840 rupees.
Ranjit Shahani, who heads the Organisation of Pharmaceutical Producers of India, says widespread compulsory licensing will jeopardize investment in innovative pharmaceuticals.
Bayer has said it will launch a legal challenge to the compulsory license, and global drugmakers have vowed to oppose the spread of such legislation.
Hamied denied that his latest move was simply an attempt to boost his share in the oncology drugs market, insisting business must be linked to “social responsibility.”
However, he said like any other business, his company, which has 23 cancer drugs, also wants sales.
“I owe it to my shareholders to be pragmatic,” he said.
Born in Lithuania to an Indian Muslim father and a Lithuanian Jewish mother, Hamied was two months old when his parents fled Europe in the 1930s under the threat of Nazi Germany.
He was raised in Mumbai and studied for a doctorate in chemistry at Cambridge University in Britain before joining Cipla, which was founded by his father.
“My father never forced me but chemistry was my best subject,” said Hamied, who became chairman of the company in 1989.
His bold step in offering cheap AIDS drugs turned out to be a smart business move.
Cipla is now the world’s largest AIDS antiretroviral drugs supplier and the publicly listed company is valued at nearly US$5 billion, while business magazine Forbes puts Hamied’s personal fortune at US$1.75 billion.
However, Hamied said poverty-racked India “can’t afford to divide people into those who can afford life-saving drugs and those who can’t.”
He believes the pharma giants should let emerging market drugmakers make copycat medicines in exchange for small royalties.
Some 95 percent of Western firms’ profits come from regulated developed markets like Japan, Europe and the US, so the pharmaceutical giants “really won’t lose out,” he added.
Even with the reduced price of generic drugs, such medicines are still beyond the reach of many of the world’s poorest, said Hamied, who confesses he has his eye on his legacy.
“I want it to be said when I leave this world that ‘he was not just a money-making machine,’” he said.
Showcasing phallus-shaped portable shrines and pink penis candies, Japan’s annual fertility festival yesterday teemed with tourists, couples and families elated by its open display of sex. The spring Kanamara Matsuri near Tokyo features colorfully dressed worshipers carrying a trio of giant phallic-shaped objects as they parade through the street with glee. The festival, as legend has it, honors a local blacksmith in the Edo Period (1603-1868) who forged an iron dildo to break the teeth of a sharp-toothed demon inhabiting a woman’s vagina that had been castrating young men on their wedding nights. A 1m black steel phallus sits in the courtyard of
JAN. 1 CLAUSE: As military service is voluntary, applications for permission to stay abroad for over three months for men up to age 45 must, in principle, be granted A little-noticed clause in sweeping changes to Germany’s military service policy has triggered an uproar after it emerged that the law requires men aged up to 45 to get permission from the armed forces before any significant stay abroad, even in peacetime. The legislation, which went into effect on Jan. 1 aims to bolster the military and demands all 18-year-old men fill out a questionnaire to gauge their suitability to serve in the armed forces, but stops short of conscription. If the “modernized” model fails to pull in enough recruits, parliament will be compelled to discuss the reintroduction of compulsory service, German
Filipino farmers like Romeo Wagayan have been left with little choice but to let their vegetables rot in the field rather than sell them at a loss, as rising oil prices linked to the Iran war drive up the cost of harvesting, labor and transport. “There’s nothing we can do,” said Wagayan, a 57-year old vegetable farmer in the northern Philippine province of Benguet. “If we harvest it, our losses only increase because of labor, transportation and packing costs. We don’t earn anything from it. That’s why we decided not to harvest at all,” he said. Soaring costs caused by the Middle East
Hungarian Prime Minister Viktor Orban’s officially declared wealth is fairly modest: some savings and a jointly owned villa in Budapest. However, voters in what Transparency International deems the EU’s most corrupt country believe otherwise — and they might make Orban pay in a general election this Sunday that could spell an end to his 16-year rule. The wealth amassed by Orban’s inner circle is fueling the increasingly palpable frustration of a population grappling with sluggish growth, high inflation and worsening public services. “The government’s communication machine worked well as long as our economic situation remained relatively good,” said Zoltan Ranschburg, a political analyst
RSS